卢克索利提尼布治疗改善了STAT3功能增强疾病患者的临床,免疫和转录异常
Feyza Bayram Catak1, Mehmet Cihangir Catak1, Royala Babayeva1
1Division of Pediatric Allergy and Immunology, Faculty of Medicine, Marmara University, Istanbul, Turkey; Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkey; Isil Berat Barlan Center for Translational Medicine, Istanbul, Turkey.
The Journal of allergy and clinical immunology
|December 4, 2024
概括
鲁克索利提尼布通过使免疫细胞群和基因表达正常化,有效治疗STAT3功能增强疾病. 这种 Janus 激酶抑制剂疗法改善了临床症状,并逆转了细胞和转录异常.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 信号传感器和转录3 (STAT3) 激活器功能增强 (GOF) 疾病的特征是淋巴增殖,自身免疫力和无法繁荣.
- 氏激酶 (JAK) 抑制剂提供症状缓解,但它们对STAT3 GOF疾病病原发生的影响尚未完全理解.
研究的目的:
- 在四名患有STAT3GOF疾病的患者中,前性评估长期使用ruxolitinib治疗的临床,免疫学和转录学效应.
- 了解鲁克索利提尼布对STAT3GOF免疫细胞动态和基因表达特征的影响.
主要方法:
- 在12个月内进行了连续的临床和免疫学评估 (毛囊T辅助细胞,调节性T细胞,细胞因子,增殖试验).
- 进行了转录基因分析和T细胞受体测序,以评估治疗引起的变化.
- 评估了天真,效应记忆和调节性T细胞种群的变化,以及细胞因子的产生.
主要成果:
- 鲁克索利提尼布证明了实质性的临床控制,增加了天真的T细胞,并减少了效应记忆和T毛囊辅助细胞.
- 转录组分析显示,STAT3向基因,干扰素通路和骨髓细胞激活标记物的正常化.
- 虽然调控性T细胞的百分比进一步下降,但细胞因子的产生保持不变;T细胞受体测序表明潜在的自身反应克隆.
结论:
- 鲁克索利提尼布有效地逆转了STAT3GOF疾病中的关键细胞和转录基因特征.
- 这项研究增强了对STAT3 GOF病理生理学的理解,并确定了监测治疗疗效的关键免疫学标志物.
相关概念视频
02:23Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
01:20The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K